Next Article in Journal
A Case of Systemic Infection Caused by Streptococcus pyogenes Oral Infection in an Edentulous Patient
Previous Article in Journal
Biomarkers and Imaging Findings of Anderson–Fabry Disease—What We Know Now
Previous Article in Special Issue
Milk’s Role as an Epigenetic Regulator in Health and Disease
Article Menu

Export Article

Open AccessReview
Diseases 2017, 5(3), 16; doi:10.3390/diseases5030016

Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer

Department of Medicine/Endocrinology, School of Medicine, University of Colorado, Ms 8106 PO Box 6511, 12801 E 17th Avenue, Aurora, Denver, CO 80010, USA; Tel.: +1-303-724-1013; Fax: +1-303-724-3920
Received: 24 April 2017 / Revised: 28 June 2017 / Accepted: 30 June 2017 / Published: 6 July 2017
View Full-Text   |   Download PDF [549 KB, uploaded 6 July 2017]   |  

Abstract

Breast cancer is one of the most common cancers and the second leading cause of cancer death in the United States. Estrogen receptor (ER)-positive cancer is the most frequent subtype representing more than 70% of breast cancers. These tumors respond to endocrine therapy targeting the ER pathway including selective ER modulators (SERMs), selective ER downregulators (SERDs) and aromatase inhibitors (AIs). However, resistance to endocrine therapy associated with disease progression remains a significant therapeutic challenge. The precise mechanisms of endocrine resistance remain unclear. This is partly due to the complexity of the signaling pathways that influence the estrogen-mediated regulation in breast cancer. Mechanisms include ER modifications, alteration of coregulatory function and modification of growth factor signaling pathways. In this review, we provide an overview of epigenetic mechanisms of tamoxifen resistance in ER-positive luminal breast cancer. We highlight the effect of epigenetic changes on some of the key mechanisms involved in tamoxifen resistance, such as tumor-cell heterogeneity, ER signaling pathway and cancer stem cells (CSCs). It became increasingly recognized that CSCs are playing an important role in driving metastasis and tamoxifen resistance. Understanding the mechanism of tamoxifen resistance will provide insight into the design of novel strategies to overcome the resistance and make further improvements in breast cancer therapeutics. View Full-Text
Keywords: epigenetics; DNA methylation; histone modification; microRNA; luminal breast cancer; tamoxifen resistance; cancer stem cells epigenetics; DNA methylation; histone modification; microRNA; luminal breast cancer; tamoxifen resistance; cancer stem cells
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Abdel-Hafiz, H.A. Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. Diseases 2017, 5, 16.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top